Eric Graban Best Practices, Development, Industry, Innovation, Manufacturing, Production

Specializing In Small And Early-Stage Injectables, Not Just Small Batches

Source: Singota Solutions By Jennifer Gray and Eric Graban, Singota Solutions For small and/or early stage pharmaceutical companies trying to advance a small-volume drug product through preclinical and clinical trials, the temptation to partner with large, well-known CDMOs for aseptic manufacturing can be alluring. Their reputation as service providers for large…
Read More
Jacob Wheeler Manufacturing, Quality Assurance, Testing

Deliver A Technical Package That Serves On-Time Injectable Project Completion

Source: Singota Solutions By William Powers, Singota Solutions Meeting drug development timelines — in particular, filling the first Phase 1 batch for an injectable’s clinical trial – is critical. Producing that initial batch requires the CDMO to gather information from a pharmaceutical client about its drug substance, drug product, and analytical…
Read More
Jacob Wheeler Development, Manufacturing, Quality Assurance, Testing

Analysis Paralysis: Navigating Early-Phase Analytical Validation

Source: Singota Solutions By Dustin Lafferty, Singota Solutions Significant confusion persists across the pharmaceutical/biopharmaceutical industry relevant to early-phase analytical development and validation. While several guidance documents serve as a de facto standard, distinguishing method validation requirements from suggestions, when and how to apply those guidelines often is not a straightforward task.…
Read More
Michelle Hoover Industry, Manufacturing, Quality Assurance, Testing

Strengthen Your IND Submission To The FDA By Conducting Microbial Challenge Studies

Strengthen Your IND Submission To The FDA By Conducting Microbial Challenge Studies Source: Singota Solutions By Ken Chomistek, Singota Solutions Microbial challenge studies are becoming increasingly common as drug products (DP) are being manufactured with different types of active pharmaceutical ingredients (API) than fifteen years ago. Peptides, proteins, monoclonal antibodies, oligonucleotides,…
Read More
Jacob Wheeler Industry, Manufacturing, Quality Assurance

Expertise And Efficiency In Small-Volume Batch Manufacturing

Expertise And Efficiency In Small-Volume Batch Manufacturing Source: Singota Solutions By Alex Cravens, Singota Solutions Demand for small-batch drug product (DP) manufacturing — from formulation to sterile fill/finish — is rising as drugs for precision medicine and large-molecule biologics gain in prominence. However, traditional fill/finish providers may consider small batch sizes…
Read More
Site Admin Innovation, Manufacturing

Strategies to Maximize Batch Yields in Aseptic Manufacturing: High Value Actives

Advances in drug and biologics discovery have allowed the development of increasingly sophisticated and highly targeted therapeutics. The active ingredients, whether small molecules or biologics, have become increasingly complex and costly to manufacture. Because of the physical properties of most biologics, the route of administration is typically parenteral and therefore it is imperative that manufacturers of sterile drug product develop strategies to maximize their yields and minimize losses throughout the finished product production process. Here are a number of considerations:

Read More
Nikki Wikholm Announcements, Manufacturing, News

Singota™ Solutions Adds World-Class Sterile Filling Technology

Singota Solutions, a life sciences contract service provider, brings new technology to the U.S. with its sterile filling expansion. BLOOMINGTON, INDIANA (PRWEB) FEBRUARY 28, 2017 Singota Solutions announced it has completed installation of the pharmaceutical industry’s most advanced manufacturing technology for use in filling injectable drug products into vials, syringes, and…
Read More